QR-kod

Safety and preliminary efficacy of adding tocilizumab to cisplatin/docetaxel for the treatment of locally advanced triple-negative breast cancer patients: prospective phase 1/2 clinical trial

Abstract Triple-negative breast cancer (TNBC) remains a challenge for clinicians due to its aggressive behavior and scarcity of effective treatment. Interleukin 6 (IL-6) is well known to contribute to poor therapeutic gain, tumor relapse, and aggressive tumor growth. Here, we have explored targeting...

Full beskrivning

Sparad:
Huvudupphov: Taher Al-Tweigeri, Asma Tulbah, Syed Akhtar, Meshari Alzahrani, Saleh Najjar, Tusnem El Hassan, Noura N. Alraouji, Kauser Suleman, Adher AlSayed, Abdelilah Aboussekhra
Materialtyp: Artigo
Språk:Inglês
Utgiven: Nature Portfolio 2026-02-01
Serie:Scientific Reports
Ämnen:
Tocilizumab
Triple-negative breast cancer
Interleukin-6
Clinical trial
Länkar:https://doi.org/10.1038/s41598-026-38465-z
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk